Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Summary

Global Markets Direct’s new report, “Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018” provides key market data on the Greece In Vitro Diagnostics market. The report provides value (USD) million data for each segment and sub-segment within seven market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the twelve market categories.
- Global corporate-level profiles of key companies operating within the Greece In Vitro Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Greece In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 What is This Report About? 10
3 In Vitro Diagnostics In Greece 11
3.1 In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018 11
3.2 In Vitro Diagnostics, Greece, Company Share (2010-2011) 17
4 Clinical Chemistry In Greece 19
4.1 Clinical Chemistry Overall Revenue, (2004-2018) 19
4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 23
4.1.2 Urine Analysis, Revenue (2004-2018) 27
4.2 Clinical Chemistry Distribution Share (2010-2011) 31
4.3 Clinical Chemistry, Greece, Company Share (2010-2011) 32
5 Genetic Testing In Greece 34
5.1 Genetic Testing Overall Revenue, (2004-2018) 34
5.2 Genetic Testing Distribution Share (2010-2011) 38
5.3 Genetic Testing, Greece, Company Share (2010-2011) 39
6 Haematology In Greece 41
6.1 Haematology Overall Revenue, (2004-2018) 41
6.1.1 Haematology Reagents, Revenue, (2004-2018) 45
6.1.2 Immunohaematology, Revenue (2004-2018) 49
6.1.3 Haemostasis, Revenue (2004-2018) 53
6.1.4 Haematology Rapid Tests, Revenue (2004-2018) 57
6.2 Haematology Distribution Share (2010-2011) 61
6.3 Haematology, Greece, Company Share (2010-2011) 62
7 Histology And Cytology In Greece 64
7.1 Histology And Cytology Overall Revenue, (2004-2018) 64
7.2 Histology And Cytology Distribution Share (2010-2011) 68
7.3 Histology And Cytology, Greece, Company Share (2010-2011) 69
8 Immuno Chemistry In Greece 71
8.1 Immuno Chemistry Overall Revenue, (2004-2018) 71
8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018) 75
8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 79
8.1.3 Endocrinology Tests, Revenue (2004-2018) 83
8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 87
8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 91
8.1.6 Immunochemistry Analyzers, Revenue (2004-2018) 95
8.2 Immuno Chemistry Distribution Share (2010-2011) 99
8.3 Immuno Chemistry, Greece, Company Share (2010-2011) 100
9 Infectious Immunology In Greece 102
9.1 Infectious Immunology Overall Revenue, (2004-2018) 102
9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 106
9.2 Infectious Immunology Distribution Share (2010-2011) 110
9.3 Infectious Immunology, Greece, Company Share (2010-2011) 111
10 Microbiology Culture In Greece 113
10.1 Microbiology Culture Overall Revenue, (2004-2018) 113
10.1.1 Microbiology Analyzers, Revenue (2004-2018) 117
10.2 Microbiology Culture Distribution Share (2010-2011) 121
10.3 Microbiology Culture, Greece, Company Share (2010-2011) 122
11 Overview of Key Companies in Greece In Vitro Diagnostics Market 124
11.1 F. Hoffmann-La Roche Ltd. 124
11.1.1 Company Overview 124
11.2 Siemens Healthcare 124
11.2.1 Company Overview 124
11.3 Abbott Laboratories 125
11.3.1 Company Overview 125
11.4 Beckman Coulter, Inc. 125
11.4.1 Company Overview 125
11.5 Ortho-Clinical Diagnostics Inc. 126
11.5.1 Company Overview 126
11.6 bioMerieux S.A. 126
11.6.1 Company Overview 126
11.7 Sysmex Corporation 127
11.7.1 Company Overview 127
11.8 Becton, Dickinson and Company 127
11.8.1 Company Overview 127
11.9 Bio-Rad Laboratories, Inc. 128
11.9.1 Company Overview 128
11.10 DiaSorin S.p.A 128
11.10.1 Company Overview 128
11.11 Qiagen N.V. 129
11.11.1 Company Overview 129
11.12 Diagnostica Stago, Inc. 129
11.12.1 Company Overview 129
11.13 Thermo Fisher Scientific Inc. 130
11.13.1 Company Overview 130
11.14 Horiba, Ltd. 130
11.14.1 Company Overview 130
11.15 Gen-Probe Incorporated 131
11.15.1 Company Overview 131
11.16 Grifols, S.A. 131
11.16.1 Company Overview 131
11.17 Life Technologies Corporation 132
11.17.1 Company Overview 132
11.18 Immucor, Inc. 132
11.18.1 Company Overview 132
11.19 Cellestis Limited 133
11.19.1 Company Overview 133
11.20 Danaher Corporation 133
11.20.1 Company Overview 133
11.21 Phadia AB 134
11.21.1 Company Overview 134
12 Appendix 135
12.1 Global Markets Direct Research Methodology 135
12.2 Definitions of Markets Covered in the Report 136
12.2.1 In Vitro Diagnostics 136
12.3 Secondary Research 147
12.4 Primary Research 147
12.5 Models 148
12.6 Forecasts 148
12.7 Expert Panel Validation 148
12.8 Currency Conversion 149
12.9 Contact Us 149
12.10 Disclaimer 149

1.1 List of Tables
Table 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018 12
Table 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Historic, 2004-2011 14
Table 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 16
Table 4: In Vitro Diagnostics, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 18
Table 5: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 20
Table 6: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 22
Table 7: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 24
Table 8: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 26
Table 9: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 28
Table 10: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 30
Table 11: Clinical Chemistry, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 31
Table 12: Clinical Chemistry, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 33
Table 13: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 35
Table 14: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 37
Table 15: Genetic Testing, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 38
Table 16: Genetic Testing, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 40
Table 17: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 42
Table 18: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 44
Table 19: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 46
Table 20: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 48
Table 21: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 50
Table 22: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 52
Table 23: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 54
Table 24: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 56
Table 25: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 58
Table 26: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 60
Table 27: Haematology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 61
Table 28: Haematology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 63
Table 29: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 65
Table 30: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 67
Table 31: Histology And Cytology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 68
Table 32: Histology And Cytology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 70
Table 33: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 72
Table 34: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 74
Table 35: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 76
Table 36: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 78
Table 37: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 80
Table 38: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 82
Table 39: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 84
Table 40: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 86
Table 41: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 88
Table 42: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 90
Table 43: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 92
Table 44: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 94
Table 45: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 96
Table 46: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 98
Table 47: Immuno Chemistry, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 99
Table 48: Immuno Chemistry, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 101
Table 49: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 103
Table 50: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 105
Table 51: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 107
Table 52: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 109
Table 53: Infectious Immunology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 110
Table 54: Infectious Immunology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 112
Table 55: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 114
Table 56: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 116
Table 57: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 118
Table 58: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 120
Table 59: Microbiology Culture, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 121
Table 60: Microbiology Culture, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 123

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018 11
Figure 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Historic, 2004-2011 13
Figure 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 15
Figure 4: In Vitro Diagnostics, Greece, Company Share (%), 2011 17
Figure 5: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 19
Figure 6: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 21
Figure 7: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 23
Figure 8: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 25
Figure 9: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 27
Figure 10: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 29
Figure 11: Clinical Chemistry, Greece, Company Share (%), 2011 32
Figure 12: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 34
Figure 13: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 36
Figure 14: Genetic Testing, Greece, Company Share (%), 2011 39
Figure 15: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 41
Figure 16: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 43
Figure 17: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 45
Figure 18: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 47
Figure 19: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 49
Figure 20: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 51
Figure 21: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 53
Figure 22: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 55
Figure 23: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 57
Figure 24: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 59
Figure 25: Haematology, Greece, Company Share (%), 2011 62
Figure 26: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 64
Figure 27: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 66
Figure 28: Histology And Cytology, Greece, Company Share (%), 2011 69
Figure 29: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 71
Figure 30: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 73
Figure 31: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 75
Figure 32: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 77
Figure 33: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 79
Figure 34: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 81
Figure 35: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 83
Figure 36: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 85
Figure 37: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 87
Figure 38: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 89
Figure 39: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 91
Figure 40: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 93
Figure 41: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 95
Figure 42: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 97
Figure 43: Immuno Chemistry, Greece, Company Share (%), 2011 100
Figure 44: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 102
Figure 45: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 104
Figure 46: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 106
Figure 47: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 108
Figure 48: Infectious Immunology, Greece, Company Share (%), 2011 111
Figure 49: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 113
Figure 50: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 115
Figure 51: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 117
Figure 52: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 119
Figure 53: Microbiology Culture, Greece, Company Share (%), 2011 122
Figure 54: Global Markets Direct Methodology 135